SOMERSET, N.J. / Feb 24, 2023 / Business Wire / Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:
Event: Cowen 43rd Annual Healthcare Conference
Location: Boston, MA
Fireside Chat Date & Time: Tuesday, March 7, 2023 at 9:50am ET
Presenter: Ying Huang, Ph.D., CEO
Event: Barclays Global Healthcare Conference
Location: Miami, FL
Fireside Chat Date & Time: Tuesday, March 14, 2023 at 10:15am ET
Presenter: Ying Huang, Ph.D., CEO
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.
| Last Trade: | US$27.14 |
| Daily Change: | 0.30 1.12 |
| Daily Volume: | 1,481,291 |
| Market Cap: | US$5.010B |
November 13, 2025 November 12, 2025 November 03, 2025 June 03, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
